Bilateral ovarian endometriomas after laparoscopic hysterectomy following adjuvant tamoxifen therapy for breast cancer: A case report

Satoshi Nishiyama*, Sotaro Hayashi, Naoki Abe, Sachino Kira, Miho Oda, Lifa Lee, Yoko To, Maki Goto, Hiroshi Tsujioka

Department of Obstetrics and Gynecology, Aso Iizuka Hospital, 3-83 Yoshiomachi, Iizuka 820-8505, Fukuoka, Japan

ARTICLE INFO

Keywords:
Tamoxifen
Tamoxifen-associated ovarian endometrioma
Ovarian endometriosis
Laparoscopic surgery

ABSTRACT

Tamoxifen, a selective estrogen receptor modulator, is widely used as adjunctive therapy for women with breast cancer. However, tamoxifen has an agonistic effect on the endometrium and may be associated with endometrial proliferation, hyperplasia, polyp formation and carcinoma. The case report describes a 50-year-old woman who developed bilateral ovarian endometriomas while taking tamoxifen for breast cancer after total laparoscopic hysterectomy. She had undergone total laparoscopic hysterectomy for multiple uterine fibroids with no ovarian pathology at age 48 years, had been diagnosed with breast cancer and had commenced tamoxifen as post-mastectomy adjuvant therapy. One year after starting tamoxifen, she developed bilateral ovarian swelling accompanied by acute abdominal pain. At laparoscopic bilateral salpingo-oophorectomy, endometriomas were visible on both ovaries. Pathological examination confirmed endometriotic cysts with no evidence of malignancy. Postoperatively, anastrozole (an aromatase inhibitor) was substituted for tamoxifen as adjuvant therapy for her breast cancer.

1. Introduction

Globally, breast cancer is the second most frequently diagnosed malignancy after lung cancer, accounting for over two million cases annually [1]. It is also the leading cause of cancer death in women worldwide. In Japan, breast cancer was the most common cancer of women in 2018, and the fifth most common cause of cancer death in women in 2019 [2].

Fewer than one-third of women with newly diagnosed breast cancer are premenopausal [3]; however, administration of adjuvant endocrine therapy for hormone receptor-positive cancers is important regardless of menopausal status, to reduce the risk of recurrence.

Tamoxifen (TAM) is widely administered to women with hormone receptor-positive breast cancer. TAM is an established adjuvant therapeutic agent for breast cancer because of its antagonistic effect on that tissue. However, TAM is also a known risk factor for endometrial cancer because of its agonistic effects on the endometrium.

Despite case reports regarding the relationship between endometriosis and TAM use, it remains unclear whether this agent induces or promotes endometriosis. We report here a woman with bilateral ovarian endometriomas that developed following TAM treatment.

2. Case Presentation

A 48-year-old premenopausal woman, gravida 1, para 1, presented with heavy menstrual bleeding. Transvaginal ultrasonography and magnetic resonance imaging (MRI) revealed one submucosal and multiple interstitial uterine fibroids. Additionally, she was anemic.

Given that her fibroids were symptomatic, a total laparoscopic hysterectomy with ovarian conservation was performed. Intraoperatively, the uterus was seen to be enlarged, but both ovaries were macroscopically normal. There was no macroscopic evidence of endometriosis on laparoscopy (Fig. 1).

Two years after the hysterectomy, she was diagnosed with breast cancer and underwent mastectomy followed by radiotherapy. She was prescribed oral tamoxifen (20 mg/day) as adjuvant therapy. No pelvic masses were detected on ultrasound sonography at that time. Three years after the hysterectomy, at the age of 51 years, she presented with lower abdominal pain of sudden onset. A 7-cm diameter, right pelvic, multilocular cyst and a left unilocular cyst were detected by contrast enhanced CT and MRI examination (Fig. 2). Bilateral endometriotic ovarian cysts were suspected and accordingly laparoscopic bilateral salpingo-oophorectomy was performed.

* Corresponding author.
E-mail address: nishiyama.biz@gmail.com (S. Nishiyama).

https://doi.org/10.1016/j.crwh.2022.e00442
Received 16 June 2022; Received in revised form 11 August 2022; Accepted 12 August 2022
Available online 18 August 2022
2214-9112/© 2022 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
At laparoscopy, the diameter of her right ovary was 4 cm and of the left ovary 7 cm. No intraperitoneal adhesions were identified. The cysts contained chocolate-like liquid (Figs. 3, 4).

She was diagnosed as having bilateral ovarian endometriotic cysts with no histopathological evidence of malignancy. Postoperatively, anastrozole (an aromatase inhibitor) was substituted for TAM.

3. Discussion

TAM has antiestrogenic activity in breast tissue, whereas it has an estrogen-like effect on the endometrium. TAM has been associated with endometrial proliferation leading to endometrial hyperplasia, polyps, endometriosis, and carcinoma [4]. Numerous reports of endometriosis developing during treatment with tamoxifen have been published [5–11] (Table 1). The Breast Cancer Prevention Trial by the National Surgical Adjuvant Breast and Bowel Project reported that women taking TAM have a greater incidence of endometriosis than do women taking a placebo (RR = 2.0). [4] However, little is known about the progression of endometriosis in women taking tamoxifen. This case report describes the development of benign ovarian endometriomas in a tamoxifen user whose ovaries were macroscopically normal before treatment.

Given the risk of malignant transformation in endometriosis [12, 13], women taking TAM should be advised to have gynecological follow-up.

4. Conclusions

We report here a case of ovarian endometriosis in a TAM user. Because TAM can stimulate endometrial tissue, women should be followed up regularly. In the present case, the ovarian endometriomas arose in a woman who had macroscopically normal ovaries before...
treatment.

Contributors

Satoshi Nishiyama contributed to patient management, data collection and analysis and drafted the manuscript. Sotaro Hayashi, Naoki Abe, Sachino Kira, Miho Oda, Lifa Lee, Yoko To, and Maki Goto contributed to data analysis and editing of the manuscript. Hiroshi Tsujioka contributed to patient management, data analysis, and editing of the manuscript.

All authors approved the final submitted article.

Funding

No funding was received for the writing of this case report.

Patient consent

Informed consent for publication of this case report was obtained from the patient.

Provenance and peer review

This article was not commissioned and was peer reviewed.

Conflict of interest statement

The authors declare that they have no conflict of interest regarding the publication of this case report.

Acknowledgments

We thank Dr. Trish Reynolds, MBBS, FRACP, from Edanz (https://jp.edanz.com/ac), for editing a draft of this manuscript.

References

[1] Hyuna Sung, Jacques Ferlay, Rebecca L. Siegel, Mathieu Laversanne, Isabelle Soerjomataram, Ahmedin Jemal, Freddie Bray, Global cancer statistics 2020. GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries, CA Cancer J. Clin. 71 (3) (2021; May) 209–249.

[2] Cancer Statistics. Cancer Information Service, National Cancer Center, Japan (National Cancer Registry, Ministry of Health, Labour and Welfare) https://ganjoho.jp/reg_stat/statistics/data/dl/en.html.

[3] National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Cancer Stat Facts: Female breast cancer. http://seer.cancer.gov/statfacts/html/breast.html (Accessed on April 16, 2019).

[4] Eva Chalas, Joseph P. Costantino, D. Lawrence Wickerham, Norman Wolmark, George C. Lewis, Cynthia Bergman, Carolyn D. Runowicz, Benign gynecologic conditions among participants in the Breast Cancer Prevention Trial, Am. J. Obstet. Gynecol. 192 (4) (2005 Apr) 1230–1237.

[5] Abad de Velasco, A. Cano, Acute abdomen due to endometriosis in a premenopausal woman taking tamoxifen, Eur. J. Obstet. Gynecol. Reprod. Biol. 109 (2) (2003 Aug 15) 234–235.

[6] L. Abad de Velasco, A. Cano, Acute abdomen due to endometriosis in a premenopausal woman taking tamoxifen, Eur. J. Obstet. Gynecol. Reprod. Biol. 109 (2) (2003 Aug 15) 234–235.

[7] M. A. Morgan, Y. Gincherman, J. J. Mikuta, Endometriosis and tamoxifen therapy, Int. J. Gynaecol. Obstet. 45 (1) (1994 Apr) 55–57.

[8] L. Abad de Velasco, A. Cano, Acute abdomen due to endometriosis in a premenopausal woman taking tamoxifen, Eur. J. Obstet. Gynecol. Reprod. Biol. 109 (2) (2003 Aug 15) 234–235.

[9] M. Ford, M. J. Turner, C. Wood, W. P. Soutter, Endometriosis developing during tamoxifen therapy, Am. J. Obstet. Gynecol. 158 (4) (1993 Aug 15) 642–644.

[10] P.G. Rose, B. Alvarez, G.T. Maclennan, Exacerbation of endometriosis as a result of premenopausal tamoxifen exposure, Am. J. Obstet. Gynecol. 183 (2) (2000 Aug) 507–508.

[11] L.R. Hajjar, W. Kim, G.H. Nolan, S. Turner, U.R. Raju, Intestinal and pelvic endometriosis presenting as a tumor and associated with tamoxifen therapy: report of a case, Obstet. Gynecol. 82 (4 Pt 2 Suppl) (1993 Oct) 642–644.

[12] In Ho Choi, So-Young Jin, Yoon Ml Jeen, Jeong Jae Lee, Dong Won Kim, Tamoxifen-associated polypoid endometriosis mimicking an ovarian neoplasm, Obstet. Gynecol. Sci. 58 (4) (2015 Jul) 327–330.

[13] P.D. DePriest, E.R. Banks, D.E. Powell, J.R. van Nagell Jr, H.H. Gallion, L.E. Puls, J. E. Hunter, R.J. Kryscio, M.B. Royalty, Endometrioid carcinoma of the ovary and endometriosis: the association in postmenopausal women, Gynecol. Oncol. 47 (1) (1992) 71–75.

[14] Susan C. Modestitt, Guillermo Tortolero-Luna, Jubilee B. Robinson, David M. Gerhenson, Judith K. Wolf, Ovarian and extranovarian endometriosis-associated cancer, Obstet. Gynecol. 100 (4) (2002) 788–795.

Table 1

| age      | pre/post menopausal | region       | period of medication |
|----------|---------------------|--------------|----------------------|
| 42       | premenopausal       | Ovary        | 19 months            |
| 37       | premenopausal       | Ovary        | 13 months            |
| 26       | premenopausal       | Ovary        | 12 months            |
| 54       | premenopausal       | Douglas’ pouch | 5 months          |
| 41       | premenopausal       | Douglas’ pouch | 1 month            |
| 55       | postmenopausal      | Douglas’ pouch, rectum | 24 months |
| 60       | postmenopausal      | Douglas’ pouch, rectum | 24 months |
| 66       | postmenopausal      | Ovary        | 48 months            |

Fig. 4. There is chocolate-like liquid in (A) the left and (B) right ovaries.

Table 1

Case reports of endometriosis developing during administration of tamoxifen [5–11].

| age       | pre/post menopausal | region        | period of medication |
|-----------|---------------------|---------------|----------------------|
| 42        | premenopausal       | Ovary         | 19 months            |
| 37        | premenopausal       | Ovary         | 13 months            |
| 26        | premenopausal       | Ovary         | 12 months            |
| 54        | premenopausal       | Douglas’ pouch | 5 months            |
| 41        | premenopausal       | Douglas’ pouch | 1 month            |
| 55        | postmenopausal      | Douglas’ pouch, rectum | 24 months |
| 60        | postmenopausal      | Douglas’ pouch, rectum | 24 months |
| 66        | postmenopausal      | Ovary         | 48 months            |

Conflict of interest statement

The authors declare that they have no conflict of interest regarding the publication of this case report.

Acknowledgments

We thank Dr. Trish Reynolds, MBBS, FRACP, from Edanz (https://jp.edanz.com/ac), for editing a draft of this manuscript.